Shareholders Sue Amgen Over Anemia Drugs

Law360, New York (April 18, 2007, 12:00 AM EDT) -- Biotech company Amgen Inc. has been hit with a class action securities lawsuit alleging that the drug maker misled shareholders by concealing the results of a clinical study involving two of its anemia drugs.

The suit, filed Wednesday in the U.S. District Court for the Central District of California, alleges that Amgen failed to disclose the results of trials for anemia drugs Epogen and Aranesp.

Epogen and Aranesp have received the approval of the U.S. Food and Drug Administration to be prescribed to fight anemia in...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.